
Sasa Jankovic
Frrelance Medical/Health Journalist/Editor/Copywriter and Author at The Pharmaceutical Journal
Yorkshire-born half Scouse half Serb. Award-winning health journalist. Journalling-for-mental-health tutor. Buy me a ☕️ https://t.co/HAfLUu1UWn
Articles
-
2 weeks ago |
pharmaceutical-journal.com | Sasa Jankovic
The use of antidepressants — particularly selective serotonin re-uptake inhibitors (SSRIs) — are associated with a “statistically substantial increased risk” of postural hypotension (PH) in older people during the first 28 days of use, according to the results of a study.
-
1 month ago |
pharmaceutical-journal.com | Antimicrobial resistance |Sasa Jankovic
More than three-quarters (79%) of pharmacies receive requests for unnecessary antibiotics from patients for minor ailments, such as colds, at least once a day, via over-the-counter drugs or during Pharmacy First consultations, a survey conducted by the National Pharmacy Association (NPA) has revealed.
-
1 month ago |
pharmaceutical-journal.com | Sasa Jankovic
The Medicines and Healthcare products Regulatory Agency (MHRA) is reviewing blood monitoring requirements for patients using clozapine and will seek views on how to improve awareness and management of the risks associated with the antipsychotic medicine, a health minister has said.
-
1 month ago |
pharmaceutical-journal.com | Sasa Jankovic
A new treatment for advanced bowel cancer has been approved by the National Institute for Health and Care Excellence (NICE) and made available on the NHS, reversing previous draft guidance that did not recommend the combined immunotherapies nivolumab (Opdivo) and ipilimumab (Yervoy). In documents supporting its decision, NICE said that clinical evidence showed the dual treatment to be effective against standard care, which is either chemotherapy or pembrolizumab.
-
1 month ago |
pharmaceutical-journal.com | Sasa Jankovic
The National Institute for Health and Care Excellence (NICE) has expanded access to cladribine (Mavenclad; Merck) for adults with active relapsing-remitting multiple sclerosis (MS), if they would otherwise be offered highly effective disease-modifying drugs. The technology appraisal guidance, published on 15 April 2025, said that cladribine can be offered to people with MS as an alternative to Ocrevus (ocrelizumab; Roche Products) or Kesimpta (ofatumumab; Novartis) on the NHS.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →X (formerly Twitter)
- Followers
- 1K
- Tweets
- 6K
- DMs Open
- Yes